Annex I

Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)

Scientific conclusions

Taking into account the PRAC Assessment Report on the PSUR(s) for colchicine, the scientific conclusions are as follows:

Taking into account all cumulative available safety data up to date, it is considered that there is at least reasonable evidence to support the potential relationship between colchicine used at therapeutic doses and the occurrence of hepatic disorders. Therefore, it is recommended an update of the product information of colchicine containing products in case this safety information is not included yet in section 4.8 of SmPC.

Given the variety of ADRs reported from post-marketing data sources regarding hepatic disorders and for consistency purposes with the information already present in some of the product information of the colchicine medicinal products authorised in the EU, it is considered that the most suitable general term to be included in the product information is "hepatotoxicity". Therefore, based upon these data, section 4.8 of the SmPC should be updated to add the ADR "Hepatotoxicity" with frequency "not known" under the SOC "Hepatobiliary disorders" in accordance with the SmPC guideline, in case no information related to hepatic ADRs are listed in section 4.8 of the SmpC. The PL should be updated accordingly.

The CMDh agrees with the scientific conclusions made by the PRAC.

Grounds for the variation to the terms of the Marketing Authorisation(s)

On the basis of the scientific conclusions for colchicine the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing colchicine is unchanged subject to the proposed changes to the product information.

The CMDh reaches the position that the marketing authorisation(s) of products in the scope of this single PSUR assessment should be varied. To the extent that additional medicinal products containing colchicine are currently authorised in the EU or are subject to future authorisation procedures in the EU, the CMDh recommends that the concerned Member States and applicant/marketing authorisation holders take due consideration of this CMDh position.

Annex II

Amendments to the product information of the nationally authorised medicinal product(s)

Amendments to be included in the relevant sections of the Product Information (new text **underlined and in bold**, deleted text ~~strike through~~)

Summary of Product Characteristics

- Section 4.8

If present, the following adverse reaction should be deleted:

- ~~Hepatic damage~~

The following adverse reaction should be added under the SOC Hepatobiliary disorders with a frequency not known:

- **Hepatotoxicity**

Package Leaflet

- Section 4

- ***Liver damage***

Annex III

Timetable for the implementation of this position

Timetable for the implementation of this position

Adoption of CMDh position:	March 2019 CMDh meeting
Transmission to National Competent Authorities of the translations of the annexes to the position:	11 May 2019
Implementation of the position by the Member States (submission of the variation by the Marketing Authorisation Holder):	10 July 2019